Global Phosphoramidite Market 2021
The global phosphoramidite market is expected to reach $2,063 million by 2032, with a compound annual growth rate (CAGR) of 7.78% during the forecast period from 2022 to 2032. This projected growth can be attributed to several factors, including the rising demand for oligonucleotides, the growing synthetic biology market, increasing partnerships and collaborations, continuous investment in research and development activities by private and public firms, and the growing prevalence of various diseases, which creates an urgent need for novel therapeutic treatments.
Phosphoramidites are highly reactive derivatives of nucleosides and serve as building blocks for oligonucleotide sequences. They are preferred over other raw materials due to their prime protecting groups. While phosphoramidite chemistry is the gold standard for DNA synthesis and has been for the past 30 years, it is most effective for producing short sequences. The chemistry’s stability and accuracy decrease as the synthesized oligonucleotide sequence lengthens. However, despite these limitations, phosphoramidite chemistry remains crucial for producing synthetic oligonucleotides used in various areas, such as primers for polymerase chain reactions, oligonucleotide-based therapies, and genetic engineering.
|No. of Pages||
USD 900 million in 2020
Type, End User, Region
|No. of Companies Mentioned||
Prior to the discovery of phosphoramidites in 1981, DNA synthesis techniques were limited in terms of the quality of DNA produced. Inefficient reactions resulted in truncated oligonucleotide sequences, and the intermediates used in the synthesis process were highly unstable, leading to damage in the growing oligonucleotide sequence. Phosphoramidites have overcome these challenges, making them fundamental for producing synthetic oligonucleotides utilized in research laboratories, pharmaceutical industries, and hospitals. The efficiency of phosphoramidite chemistry in synthesizing short DNA sequences has contributed to its continued prominence in the industry.
Emerging technologies are unlikely to replace phosphoramidite chemistry, as there is a growing demand for primers and short-length DNA sequences in pharmaceuticals, synthetic biology, and molecular diagnostic industries. Synthetic DNA plays a vital role in the discovery and engineering of biological pathways, making DNA synthesis a significant breakthrough. As a result, the phosphoramidite market is expected to experience substantial growth during the forecast period.
Phosphoramidite chemistry involves combining individual phosphoramidite monomers to form an oligonucleotide sequence, typically ranging from 60 to 100 nucleotides in length. The manufacturing process is carried out chemically and under strict control. Various phosphoramidites, such as deoxyamidites and 2′-modified (MOE) amidites, are widely accepted as starting materials for oligonucleotide synthesis.
The global phosphoramidite market is dynamic and rapidly evolving, creating opportunities for life sciences companies. Companies already involved in phosphoramidite development are striving to introduce diverse manufacturing options to enhance the quality of oligonucleotides. Major players, including Merck KGaA, Maravai LifeSciences Holdings, Inc., LGC Science Group Holdings Limited, and Thermo Fisher Scientific Inc., are heavily investing in research and development for their phosphoramidite products.
There are several demand drivers for the global phosphoramidite market, including the increasing applications of synthetic nucleotides in therapeutics and the growth of synthetic biology. However, the market may face limitations due to challenges in developing long nucleotide sequences and competition from emerging DNA synthesis technologies.
The market is segmented based on various factors, including type, end user, and region.
Segmentation by Type
Segmentation by End User
Pharmaceutical and Biotechnology Companies
Synthetic Biology and Research Institutes
Segmentation by Region
The increasing demand for DNA phosphoramidites in the synthetic biology, pharmaceutical, diagnostic, and related industries is driving growth in research and development activities. As a result, the DNA phosphoramidites segment dominated the market with a share of 74.30% in 2021. DNA, the fundamental component of living organisms, serves as the basis for DNA phosphoramidites, which are widely used across the industry. Their stable nucleic acid monomer structure enables efficient solid-phase DNA synthesis by converting them into highly reactive components. These phosphoramidites possess various chemical structures, which can be chemically reconstructed to form the four phosphate groups found in DNA molecules. The use of DNA phosphoramidites has significantly enhanced the speed and selectivity of internucleosidic network formation. Synthetic DNA holds immense potential for numerous applications.
Among the different end-user segments, the pharmaceutical and biotechnology companies segment held the largest market share in 2021, accounting for 47.50%. Pharmaceutical companies are at the forefront of adopting oligonucleotides as therapeutic agents. Particularly in regions such as North America and Europe, pharmaceutical companies are increasingly exploring the use of oligonucleotides to develop novel treatments for various human diseases and improve patient care. Currently, there are 386 interventional drugs under evaluation for multiple diseases, including rare disorders, central nervous system diseases, and infectious diseases. Chemical synthesis of oligonucleotides accounts for 76% of these investigational drugs.
North America emerged as the dominant region in the global phosphoramidite market in 2021, and it is expected to maintain this position during the forecast period. This can be attributed to the presence of key market players in the United States and the growing demand for innovative treatment options in research, diagnostics, and synthetic biology. Additionally, the rising prevalence of infectious diseases, genetic disorders, chronic diseases (such as breast cancer, lung cancer, melanoma, and leukemia), and neurodegenerative diseases contribute to North America’s market dominance. However, the Asia-Pacific region, consisting of several emerging economies, is projected to exhibit the highest compound annual growth rate (CAGR) of 8.66% between 2022 and 2032. In 2021, North America accounted for 41.30% of the global phosphoramidite market. The market is expected to reach $809 million by 2032, growing at a CAGR of 7.27% during the forecast period. Factors such as the presence of key market players in the United States, an aging population, the need for innovative treatment options in research, diagnostics, and synthetic biology, and the increasing prevalence of infectious diseases, genetic disorders, and chronic diseases are driving the growth of the phosphoramidite market in North America.
The selection of profiled companies is based on inputs obtained from primary experts and an analysis of the company’s coverage, product portfolio, and market penetration.
Key companies profiled in this report include Biosynth Carbosynth, Bioneer Corporation, Lumiprobe Corporation, QIAGEN N.V., Danaher Corporation (IDT), TriLink BioTechnologies, Creative Biolabs, PolyOrg, Inc., Hongene Biotech Corporation, ChemGenes, BOC Sciences, Tokyo Chemical Industry Co., Ltd. (TCI), LGC Science Group Holdings Limited, AAT Bioquest, Inc., Thermo Fisher Scientific, Inc., Merck KGaA.
Recent Industry Developments
In August 2019, the company acquired 75% of the ordinary capital of Biomed Pharmaceutical Limited, the parent company of Toronto Research Chemicals Inc.
In July 2022, TriLink BioTechnologies expanded the responsibility of its R&D leadership team to oversee the company’s scientific direction and research and development strategy.
In May 2022, TriLink BioTechnologies announced a cooperative agreement with the Department of Defense, including funding for the expansion of its nucleic acid production facility in San Diego, California.
In November 2021, Biosynth Carbosynth acquired the raw material manufacturing unit of Kexing Biopharmaceutical Co., Ltd. located in Jinan, China. This acquisition was aimed at expanding operations and increasing production volume and capacity. The facility covers an area of over 30,000 square meters.
In November 2021, prominent investment firm KKR made an undisclosed investment and acquired Biosynth Carbosynth from its founders, Armira and Dr. Urs Spitz. However, senior management will retain a significant ownership stake, and KKR will contribute as a strategic partner. KKR plans to facilitate and accelerate the expansion of the company’s product portfolio and geographic presence, as well as enhance its capabilities.
Key Questions Answered
What are the primary market drivers, challenges, and opportunities in the global phosphoramidite market?
What are the main development strategies being implemented by major players to maintain competitiveness in the market?
Which type of phosphoramidite, developed by leading and emerging players, dominates the market?
What is the impact of COVID-19 on the global phosphoramidite market?
How is each segment of the market expected to grow from 2022 to 2032, during the forecast period?
Which companies are expected to be highly disruptive in the future, and what factors contribute to this anticipation?